Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Didox (NSC-324360) 是一种合成的核糖核苷酸还原酶抑制剂,可降低患有痴呆症的 HIV 患者大脑中氧化损伤标志物的水平。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 218 | 现货 | ||
5 mg | ¥ 460 | 现货 | ||
10 mg | ¥ 663 | 现货 | ||
25 mg | ¥ 1,390 | 现货 | ||
50 mg | ¥ 2,160 | 现货 | ||
100 mg | ¥ 3,320 | 现货 | ||
500 mg | ¥ 7,290 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 492 | 现货 |
产品描述 | Didox (NSC-324360) is a synthetic ribonucleotide reductase (RR) inhibitor that has been found to reduce the levels of oxidative injury markers in the brains of HIV patients with dementia. |
体外活性 | Didox induced cell death and that this effect was suppressed by iron supplementation.?Cell treatments with didox caused changes of cellular iron content, TfR1 and ferritin levels comparable to those caused by the iron chelators, deferoxamine (DFO) and deferiprone (DFP).Didox is a bidentated iron chelator with two theoretical possible positions for the binding and among them that with the two hydroxyls of the catechol group acting as ligands is the more likely one. The iron chelating property of didox may contribute to its antitumor activity not only blocking the formation of the tyrosil radical on Tyr122 (such as HU) on RRM2 (essential for its activity) but also sequestering the iron needed by this enzyme and to the cell proliferation[1]. |
体内活性 | Didox treatment of mouse bone marrow-derived mast cells (BMMC) reduced IgE-stimulated degranulation and cytokine production, including IL-6, IL-13, TNF and MIP-1a (CCL3)[2]. |
细胞实验 | The cells were seeded in a 96-well plate (at a density of 2 × 10^3 cells for HA22T/VGH;?1.5 × 103 cells for HuH7) and exposed to various concentrations of didox and only HA22T/VGH also to hydroxyurea, DFO or DFP (0, 1, 10, 25, 50, 100, 200 and 500 μM) for 24, 48 and 72 h. In other experiments, HA22T/VGH were seeded in 96-well plates and treated with a single dose of didox, HU, DFO, DFP alone or in combination with increasing doses of FAC (25, 50, 100, 200 and 400 μM) for 48–72 h. In other type of treatment,?HA22T/VGH cells were or pre-treated for 16 h with a single dose of didox (200 μM) and then treated in combination with FAC (400–800 μM) or directly in combination didox-FAC for 48–72 h.Cell viability was evaluated with an MTT assay.?After the indicated time points and treatments, the supernatant was removed and 100 μL of the MTT solution (0.5 mg/mL) diluted in the cell medium was added to the wells.?After 3.5 h of incubation at 37 °C and 5% CO2, the MTT medium was removed and 75 μL of DMSO was added to each well.?Plates were shaken for 15 min at 37 °C until complete dissolution and absorbance was measured at 540 nm emission wavelengths.?Average percentage of cell viability at each concentration was calculated using Microsoft Excel 2016 software[1]. |
别名 | 3,4-二羟基苯甲羟肟酸, NSC-324360 |
分子量 | 169.13 |
分子式 | C7H7NO4 |
CAS No. | 69839-83-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (591.26 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 5.9126 mL | 29.5631 mL | 59.1261 mL | 147.8153 mL |
5 mM | 1.1825 mL | 5.9126 mL | 11.8252 mL | 29.5631 mL | |
10 mM | 0.5913 mL | 2.9563 mL | 5.9126 mL | 14.7815 mL | |
20 mM | 0.2956 mL | 1.4782 mL | 2.9563 mL | 7.3908 mL | |
50 mM | 0.1183 mL | 0.5913 mL | 1.1825 mL | 2.9563 mL | |
100 mM | 0.0591 mL | 0.2956 mL | 0.5913 mL | 1.4782 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Didox 69839-83-4 Cell Cycle/Checkpoint DNA Damage/DNA Repair DNA/RNA Synthesis NSC 324360 Inhibitor 3,4-二羟基苯甲羟肟酸 inhibit NSC-324360 NSC324360 inhibitor